MX2023002161A - Composiciones y metodos para enfermedades neurologicas. - Google Patents
Composiciones y metodos para enfermedades neurologicas.Info
- Publication number
- MX2023002161A MX2023002161A MX2023002161A MX2023002161A MX2023002161A MX 2023002161 A MX2023002161 A MX 2023002161A MX 2023002161 A MX2023002161 A MX 2023002161A MX 2023002161 A MX2023002161 A MX 2023002161A MX 2023002161 A MX2023002161 A MX 2023002161A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- neurological diseases
- engineered receptors
- modulating
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063068890P | 2020-08-21 | 2020-08-21 | |
| PCT/US2021/046915 WO2022040535A2 (en) | 2020-08-21 | 2021-08-20 | Compositions and methods for neurological diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002161A true MX2023002161A (es) | 2023-05-18 |
Family
ID=80350587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002161A MX2023002161A (es) | 2020-08-21 | 2021-08-20 | Composiciones y metodos para enfermedades neurologicas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240317834A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4200020A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023538130A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230061409A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116802201A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021329529A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023003167A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3192604A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300816A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002161A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022040535A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117487904B (zh) * | 2023-12-28 | 2024-05-31 | 湖南家辉生物技术有限公司 | Gabrb3基因突变体、突变体蛋白、试剂、试剂盒及应用 |
| CN119331917B (zh) * | 2024-10-28 | 2025-10-17 | 北京爱思益普生物科技股份有限公司 | 能够表达GlyR α1/β型GlyR的细胞株及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311984A (en) * | 2016-07-07 | 2024-06-01 | Hughes Howard Med Inst | Modified ligand-gated ion channels and methods of use |
| IL274702B2 (en) * | 2017-11-27 | 2026-04-01 | Coda Biotherapeutics Inc | Compounds and methods for neurological diseases |
| JP7781052B2 (ja) * | 2019-08-21 | 2025-12-05 | トレイムス バイオ, インコーポレイテッド | 神経学的疾患のための組成物および方法 |
-
2021
- 2021-08-20 AU AU2021329529A patent/AU2021329529A1/en active Pending
- 2021-08-20 CN CN202180070391.2A patent/CN116802201A/zh active Pending
- 2021-08-20 US US18/022,358 patent/US20240317834A1/en active Pending
- 2021-08-20 EP EP21859205.3A patent/EP4200020A4/en active Pending
- 2021-08-20 IL IL300816A patent/IL300816A/en unknown
- 2021-08-20 CA CA3192604A patent/CA3192604A1/en active Pending
- 2021-08-20 JP JP2023512700A patent/JP2023538130A/ja active Pending
- 2021-08-20 BR BR112023003167A patent/BR112023003167A2/pt unknown
- 2021-08-20 KR KR1020237009591A patent/KR20230061409A/ko active Pending
- 2021-08-20 WO PCT/US2021/046915 patent/WO2022040535A2/en not_active Ceased
- 2021-08-20 MX MX2023002161A patent/MX2023002161A/es unknown
-
2026
- 2026-01-22 JP JP2026008871A patent/JP2026082870A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240317834A1 (en) | 2024-09-26 |
| IL300816A (en) | 2023-04-01 |
| BR112023003167A2 (pt) | 2023-05-02 |
| JP2026082870A (ja) | 2026-05-19 |
| WO2022040535A2 (en) | 2022-02-24 |
| WO2022040535A3 (en) | 2022-03-31 |
| EP4200020A4 (en) | 2024-11-20 |
| AU2021329529A1 (en) | 2023-04-27 |
| EP4200020A2 (en) | 2023-06-28 |
| JP2023538130A (ja) | 2023-09-06 |
| CA3192604A1 (en) | 2022-02-24 |
| AU2021329529A9 (en) | 2025-03-13 |
| KR20230061409A (ko) | 2023-05-08 |
| CN116802201A (zh) | 2023-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202408862B (en) | Compositions and methods for neurological diseases | |
| Muir et al. | Recent advances in the therapeutic uses of chondroitinase ABC | |
| Levin et al. | The bioelectric code: An ancient computational medium for dynamic control of growth and form | |
| Choi et al. | Epidural electrical stimulation for spinal cord injury | |
| WO2009033027A3 (en) | Suppression of scn9a gene expression and/or function for the treatment of pain | |
| Grefkes et al. | Noninvasive brain stimulation after stroke: it is time for large randomized controlled trials! | |
| AU2018372763A1 (en) | Materials and methods for treatment of autosomal dominant Retinitis Pigmentosa | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| MX2023009682A (es) | Inhibidores de tyk2 y sus usos. | |
| WO2022040535A3 (en) | Compositions and methods for neurological diseases | |
| IL225192A (en) | Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury | |
| DE602004020061D1 (de) | Behandlung von autoimmunkrankheit bei einem patienten mit unzureichendem ansprechen auf einen tnf-alpha-hemmer | |
| WO2022195074A3 (en) | Gene therapy composition and treatment of right ventricular arrhythmogenic cardiomyopathy | |
| MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| MY168084A (en) | Methods for treating and/or reversing neurodegenerative diseases and/or disorders | |
| MX2019012176A (es) | Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral. | |
| WO2010018996A3 (ko) | 인간 신경줄기세포 및 이를 이용한 중추 또는 말초 신경계 질환 및 손상 치료용 약학적 조성물 | |
| Manser-Smith et al. | A common representation of fingers and toes | |
| WO2023159208A3 (en) | Compositions and methods for neurological diseases | |
| MX2021013351A (es) | Terapias de combinacion. | |
| Zhang et al. | Analysis of the effect of combined rehabilitation training and transcutaneous vagus nerve electrical stimulation on promoting central nervous system remodeling in stroke patients | |
| BR112019003912A2 (pt) | composição, método para criação de um hidrogel, matriz, hidrogel, método para indução da formação ou regeneração de um tecido neuronal, método para tratamento de uma lesão do nervo e método para prevenção ou tratamento de choque neurogênico após lesão do nervo | |
| Liu et al. | Theory-driven EEG indexes for tracking motor recovery and predicting the effects of hybridizing tDCS with mirror therapy in stroke patients | |
| Gupta et al. | Transcranial magnetic stimulation therapy in spastic cerebral palsy children improves motor activity |